Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions
Rheumatology & Autoimmunity · 2022-12 · 2 (4) · 230-236
DOI: 10.1002/rai2.12050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology & Autoimmunity, online erschienen am 03.11.2022. Verfasst von Lijuan Yang und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Although antinuclear antibodies (ANAs), anti‐SSA and anti‐Ro52, are present in immunoglobulin preparations, it is unknown whether intravenous immunoglobulin (IVIG) therapy influences the testing of serum autoantibodies in patients with connective tissue diseases (CTDs). The present study aimed to investigate the dynamic change over time of serum ANA‐related autoantibodies in patients with CTDs receiving IVIG therapy.
Methods
Serum ANA‐related autoantibodies were monitored in two patients with CTD before IVIG therapy and at different times after therapy. These autoantibodies were tested in different batches of immunoglobulin preparations from seven pharmaceutical companies.
Results
One patient developed a new ANA pattern (cytoplasmic dense fine speckled pattern, AC‐19) just after IVIG therapy. Both patients developed de novo positivity for AMA‐M2 and anti‐SSA, but returned negative 1 month after IVIG therapy. The residual liquid in patients' immunoglobulin preparations showed positive ANAs with a high titer of AC‐19 (1:640), a low titer of the nuclear fine speckled pattern (AC‐4, 1:80), positive AMA‐M2, and positive anti‐SSA. ANA‐related autoantibodies were tested in 16 batches of immunoglobulin preparations and all had positive ANAs with two patterns: AC‐19 (1:640 or 1:320) and AC‐4 (1:80). AMA‐M2 and anti‐SSA were positive in 100% of the batches.
Conclusion
Our study highlights high‐titer AMA‐M2 autoantibodies in immunoglobulin preparations and suggests their transient transfer into a patient's circulation via IVIG therapy. To avoid incorrect clinical decisions based on postinfusion antibody titers, our data recommend retesting 1–2 months after high‐dose IVIG immunomodulatory treatment.
Zitieren
APA
Yang, L., Wei, X., Li, Q., Li, H., Ouyang, Z., Zeng, A., Zheng, D., Dai, L., & Mo, Y. (2022). Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions. Rheumatology & Autoimmunity, 2(4), 230-236. https://doi.org/10.1002/rai2.12050
Vancouver
Yang L, Wei X, Li Q, Li H, Ouyang Z, Zeng A, et al. Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions. Rheumatology & Autoimmunity. 2022;2(4):230-236. doi:10.1002/rai2.12050
BibTeX
@article{Yang2022,
author = {Yang, Lijuan and Wei, Xiuning and Li, Qianhua and Li, Honggui and Ouyang, Zhiming and Zeng, Aiqi and Zheng, Donghui and Dai, Lie and Mo, Yingqian},
title = {Transient positive antimitochondrial M2 in sera of patients with connective tissue diseases after intravenous immunoglobulin infusions},
journal = {Rheumatology & Autoimmunity},
year = {2022},
volume = {2},
number = {4},
pages = {230--236},
doi = {10.1002/rai2.12050}
}
EUVIMED